The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Expansion Is Predicted For The Andexxa (Ondexxya) Market Between 2026 And 2030?
Growth observed in the historic period stemmed from widespread use of factor xa inhibitors, emergency bleeding incidents, regulatory approval of reversal agents, hospital critical care demand, and aging population.
The anticipated expansion during the forecast period is driven by several factors, including an increase in the prevalence of cardiovascular diseases, a rise in anticoagulant prescriptions, the broadening of trauma care services, enhancements in emergency protocols, and a growing number of surgical interventions.
Key developments projected for the forecast period involve an escalating requirement for anticoagulant reversal, the advancement of emergency bleeding management techniques, critical care therapies predominantly delivered within hospital settings, a greater adoption of Factor Xa inhibitors, and a strong focus on solutions that facilitate rapid hemostasis.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19972&type=smp
What Key Drivers Are Influencing The Growth Of The Andexxa (Ondexxya) Market?
The rising prevalence of bleeding disorders is anticipated to drive the expansion of the andexxa (ondexxya) market in the coming years. These conditions involve impairments in the blood’s clotting ability, resulting in excessive or prolonged bleeding. The increase in bleeding disorders can be attributed to better diagnostic methods, heightened public awareness, genetic factors, and an aging demographic, all contributing to their greater recognition and detection. Andexxa (Ondexxya) plays a vital role in managing bleeding disorders by quickly reversing the anticoagulant effects of factor Xa inhibitors, thereby averting critical bleeding events in urgent scenarios. For example, in July 2025, the National Blood Authority, a blood management agency based in Australia, reported that 2,797 patients were living with von Willebrand disease (VWD) in 2023–2024, an increase from 2,669 patients in 2022–2023. Consequently, the growing incidence of bleeding disorders is fueling the growth of the andexxa (ondexxya) market.
Which Market Segments Are Examined In The Andexxa (Ondexxya) Market Study?
The andexxa (ondexxya) market covered in this report is segmented –
1) By Indication: Reversal Of Bleeding Caused By Factor Xa Inhibitors, Acute Major Bleeding Events, Emergency Surgery Or Procedures
2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
3) By End User: Adult, Geriatric, Pediatric
Which Trends Are Influencing The Andexxa (Ondexxya) Market?
Key companies active in the Andexxa market are concentrating on developing advanced anticoagulant reversal therapies to enhance patient safety during critical bleeding episodes. Reversal therapy serves as a targeted intervention that neutralizes the effects of anticoagulant drugs, quickly restoring normal clotting function and reducing the risk of fatal bleeding. For example, in January 2024, AstraZeneca India obtained CDSCO approval to import and distribute andexanet alfa for life-threatening or refractory bleeding caused by Factor Xa inhibitors like apixaban and rivaroxaban. This recently approved treatment involves an initial intravenous bolus administered over 15–30 minutes, followed by a 2-hour infusion. Andexanet alfa has exhibited efficacy and safety in clinical trials involving major bleeding, facilitates early re-initiation of anticoagulation following an event, is generally well-tolerated, and addresses a significant unmet need for patients on novel oral anticoagulants.
Who Are The Primary Competitors In The Andexxa (Ondexxya) Market?
Major companies operating in the andexxa (ondexxya) market are AstraZeneca Plc
Read the full andexxa (ondexxya) market report here:
https://www.thebusinessresearchcompany.com/report/andexxa-ondexxya-global-market-report
Which Region Is Expected To Register The Fastest Growth In The Andexxa (Ondexxya) Market?
North America was the largest region in the andexxa (ondexxya) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the andexxa (ondexxya) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Andexxa (Ondexxya) Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=19972&type=smp
Browse Through More Reports Similar to the Global Andexxa (Ondexxya) Market 2026, By The Business Research Company
Hexane Market Report 2026
https://www.thebusinessresearchcompany.com/report/hexane-global-market-report
Esg Finance Market Report 2026
https://www.thebusinessresearchcompany.com/report/esg-finance-global-market-report
Data Lake Market Report 2026
https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model